Aman Al Hamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aman Al Hamed has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Abir Majed
Dubai Pharmacy College for Girls, Dubai Medical University, Dubai, UAE
1 shared publication- Alok Sharma
NeuroGen Brain & Spine Institute, Nerul, India
1 shared publication - Eid Alatwi
Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia
1 shared publication Gazala Afreen Khan
Department of Pharmaceutical Sciences, Dubai Pharmacy College for Girls, Dubai Medical University, Dubai, UAE
1 shared publication- Gopukumar Sivakumar Thangam
Nanobioinformatics Unit, Department of General Surgery, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha Medical College and Hospital, Saveetha University, Chennai, India
1 shared publication - Madhumita Saha
Institute of Nano science and Technology, Mohali, Knowledge City, Sector 81, Mohali- 140306, Punjab, India, British Indian Ocean Territory
1 shared publication
Latest Publications
- 16 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 222
CRISPR-Enabled functional genomics in hPSCs-derived neural models for autism spectrum disorder
- 16 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 222
CRISPR-Enabled functional genomics in hPSCs-derived neural models for autism spectrum disorder
- Open Access
- 25 July 2025
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 24 (3) , 799-806
Methylenetetrahydrofolate Reductase (Mthfr C677T) Gene Polymorphism Effect on Development of Diabetic Nephropathy in Arab Patients with Type 2 Diabetes Mellitus
Background Genetic susceptibility to diabetic nephropathy (DN) has been well-recognized. The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a critical role in homocysteine metabolism. Variations in the MTHFR gene, particularly the C677T variant, have been implicated in the development of macrovascular and microvascular complications. Objectives This study investigates the relationship between the MTHFR C677T genotype and the occurrence of diabetic nephropathy in type 2 diabetes mellitus (T2DM) patients. Methods A total of 50 T2DM patients were analyzed for urinary albumin/creatinine ratio, which was used to classify them into two groups: 26 patients without nephropathy and 24 with nephropathy. Additionally, the study included 30 first-degree relatives (FDRs) of diabetic patients and 20 healthy controls. Diagnostic tests performed included fasting blood glucose, HbA1c, and serum creatinine levels. Plasma total homocysteine levels were measured using a chemiluminescent assay, and the MTHFR C677T polymorphism was analyzed using PCR-restriction fragment length polymorphism (RFLP). Results Among T2DM patients with nephropathy, the distribution of MTHFR genotypes (CC homozygous, CT heterozygous, and TT homozygous) was 20.8%, 54.2%, and 25%, respectively. The T allele frequency was significantly higher in patients with nephropathy (69.2%) compared to those without nephropathy (23.1%), normal controls (26.7%), and FDRs (30%). There was no significant difference in MTHFR genotype or allele frequency between T2DM patients without nephropathy, FDRs, and healthy controls (p < 0.05). The T allele showed a strong association with the development of diabetic nephropathy. Additionally, plasma homocysteine levels were significantly elevated in individuals with TT or CT genotypes compared to those with the CC genotype, with higher levels correlating with the progression of nephropathy. Conclusion The findings suggest that the C677T mutation in the MTHFR gene predisposes T2DM patients to diabetic nephropathy. The presence of the T allele may elevate plasma homocysteine levels, contributing to the progression of nephropathy toward end-stage renal failure. These results highlight the potential role of the MTHFR C677T variant as a genetic marker for susceptibility to diabetic nephropathy in T2DM patients. BJMS, Vol. 24 No. 03 July’25 Page : 799-806
- 25 July 2025
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 24 (3) , 799-806
Open AccessMethylenetetrahydrofolate Reductase (Mthfr C677T) Gene Polymorphism Effect on Development of Diabetic Nephropathy in Arab Patients with Type 2 Diabetes Mellitus
Background Genetic susceptibility to diabetic nephropathy (DN) has been well-recognized. The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a critical role in homocysteine metabolism. Variations in the MTHFR gene, particularly the C677T variant, have been implicated in the development of macrovascular and microvascular complications. Objectives This study investigates the relationship between the MTHFR C677T genotype and the occurrence of diabetic nephropathy in type 2 diabetes mellitus (T2DM) patients. Methods A total of 50 T2DM patients were analyzed for urinary albumin/creatinine ratio, which was used to classify them into two groups: 26 patients without nephropathy and 24 with nephropathy. Additionally, the study included 30 first-degree relatives (FDRs) of diabetic patients and 20 healthy controls. Diagnostic tests performed included fasting blood glucose, HbA1c, and serum creatinine levels. Plasma total homocysteine levels were measured using a chemiluminescent assay, and the MTHFR C677T polymorphism was analyzed using PCR-restriction fragment length polymorphism (RFLP). Results Among T2DM patients with nephropathy, the distribution of MTHFR genotypes (CC homozygous, CT heterozygous, and TT homozygous) was 20.8%, 54.2%, and 25%, respectively. The T allele frequency was significantly higher in patients with nephropathy (69.2%) compared to those without nephropathy (23.1%), normal controls (26.7%), and FDRs (30%). There was no significant difference in MTHFR genotype or allele frequency between T2DM patients without nephropathy, FDRs, and healthy controls (p < 0.05). The T allele showed a strong association with the development of diabetic nephropathy. Additionally, plasma homocysteine levels were significantly elevated in individuals with TT or CT genotypes compared to those with the CC genotype, with higher levels correlating with the progression of nephropathy. Conclusion The findings suggest that the C677T mutation in the MTHFR gene predisposes T2DM patients to diabetic nephropathy. The presence of the T allele may elevate plasma homocysteine levels, contributing to the progression of nephropathy toward end-stage renal failure. These results highlight the potential role of the MTHFR C677T variant as a genetic marker for susceptibility to diabetic nephropathy in T2DM patients. BJMS, Vol. 24 No. 03 July’25 Page : 799-806